Depression screening in adults by pharmacists in the community: a systematic review.
adult
community
depression
pharmacist
screening
Journal
The International journal of pharmacy practice
ISSN: 2042-7174
Titre abrégé: Int J Pharm Pract
Pays: England
ID NLM: 9204243
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
16
12
2019
revised:
01
06
2020
accepted:
06
07
2020
pubmed:
11
8
2020
medline:
6
7
2021
entrez:
11
8
2020
Statut:
ppublish
Résumé
Improving the identification of depression in adults in primary care can produce clinical and economic benefits. Community Pharmacists may play a role in screening for depression. To systematically review and evaluate the evidence for the feasibility, impact and cost-effectiveness of community pharmacists screening adults for depression. An electronic literature search using the databases EMBASE, PubMed and CINAHL Complete from January 2000 to September 2019 was undertaken to identify studies involving community pharmacists screening for depression. Data relating to sample size, population demographics and medical conditions of adults screened were extracted. Details around the screening model, process-related outcomes, clinical outcomes and economic outcomes were also extracted. Ten studies using eight unique depression screening tools were identified. Ease of administration was the most common selection criterion (n = 4) while no reason was given in four studies. Seven studies reported that through screening, pharmacists could identify adults with undiagnosed depression. Pharmacists referred adults screening positive for assessment in seven studies and followed up participants in two studies. No study assessed the impact of screening on depressive symptoms or the cost-effectiveness of pharmacists screening for depression. Community pharmacists are able to use depression screening tools to identify undiagnosed adults having symptoms of depression. However, there is little evidence around the impact of this screening on clinical and economic outcomes. Larger, well-designed studies that use a highly accurate, easily administered screening tool and include patient referral and follow-up and pharmacist training are warranted to provide evidence on the impact of community pharmacists screening adults for depression.
Sections du résumé
BACKGROUND
BACKGROUND
Improving the identification of depression in adults in primary care can produce clinical and economic benefits. Community Pharmacists may play a role in screening for depression.
OBJECTIVE
OBJECTIVE
To systematically review and evaluate the evidence for the feasibility, impact and cost-effectiveness of community pharmacists screening adults for depression.
METHODS
METHODS
An electronic literature search using the databases EMBASE, PubMed and CINAHL Complete from January 2000 to September 2019 was undertaken to identify studies involving community pharmacists screening for depression. Data relating to sample size, population demographics and medical conditions of adults screened were extracted. Details around the screening model, process-related outcomes, clinical outcomes and economic outcomes were also extracted.
RESULTS
RESULTS
Ten studies using eight unique depression screening tools were identified. Ease of administration was the most common selection criterion (n = 4) while no reason was given in four studies. Seven studies reported that through screening, pharmacists could identify adults with undiagnosed depression. Pharmacists referred adults screening positive for assessment in seven studies and followed up participants in two studies. No study assessed the impact of screening on depressive symptoms or the cost-effectiveness of pharmacists screening for depression.
CONCLUSION
CONCLUSIONS
Community pharmacists are able to use depression screening tools to identify undiagnosed adults having symptoms of depression. However, there is little evidence around the impact of this screening on clinical and economic outcomes. Larger, well-designed studies that use a highly accurate, easily administered screening tool and include patient referral and follow-up and pharmacist training are warranted to provide evidence on the impact of community pharmacists screening adults for depression.
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
428-440Subventions
Organisme : British Heart Foundation
ID : CH/09/002/26360
Pays : United Kingdom
Informations de copyright
© 2020 Royal Pharmaceutical Society.
Références
Goldney RD et al. Major depression and its associated morbidity and quality of life in a random, representative Australian community sample. Aust N Z J Psychiatry 2000; 34: 1022-1029.
Australian Institute of Health and Welfare. Australian Burden of Disease Study: impact and causes of illness and death in Australia 2011, [online] 2016 http://www.aihw.gov.au/publication-detail (accessed 12 January 2019).
Katon WJ. Epidemiology and treatment of depression in patients with chronic medical illness. Dialogues Clin Neurosci 2011; 13: 7-23.
Oh DH et al. Multiple chronic diseases are risk factors for depressive symptoms: Results of a 2009 Korean community health survey. International Psychogeriatrics 16th International Congress of the International Psychogeriatric Association; October 2013; Seoul South Korea: Cambridge University Press; 2013. p. S95.
Patten SB. Long-term medical conditions and major depression in a Canadian population study at waves 1 and 2. J Affective Disorders 2001; 63: 35-41.
Health Quality Ontario. Screening and management of depression for adults with chronic diseases: an evidence-based analysis [online] Ontario Health Technology Assessment Series; 2013 http://www.hqontario.ca/en/documents/eds/2013/full-report-OCDMdepression-screening.pdf (accessed 28 November 2018).
Sobocki P et al. Cost of depression in Europe. J Mental Health Policy Econom 2006; 9: 87-98.
Greenberg PE et al. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry 2015; 76: 155-162.
Lee Y-C et al. Cost of high prevalence mental disorders: Findings from the 2007 Australian National Survey of Mental Health and Wellbeing. Aust N Z J Psychiatry 2017; 51: 1198-1211.
National Institute for Clinical Excellence. Depression: management of depression in primary and secondary care Clinical Guideline 23, [online] NICE Guideline: quick reference guide; 2004 www.nice.org.uk/CG023NICEguideline (accessed 16 November 2018).
Siu AL et al. Screening for depression in adults: US preventive services task force recommendation statement. J Am Med Assoc 2016; 315: 380-387.
Maimone RM, Marhatta A. The rate of depression screening at a federally qualified community health center. Health Services Res Managerial Epidemiol 2015; 2: 2333392815613057.
Jani BD et al. Challenges and implications of routine depression screening for depression in chronic disease and multimorbidity: a cross sectional study. PLoS ONE [Electronic Resource]. 2013; 8: e74610.
Voinov B et al. Depression and chronic diseases: It is time for a synergistic mental health and primary care approach. Primary Care Companion J Clin Psychiatry 2013; 15: PCC.12r01468.
Australian Institute of Health and Welfare. Australia's Health 2018: In brief Cat. no. AUS 222 [online] Australia’s health; 2018 https://www.aihw.gov.au/getmedia/fe037cf1-0cd0-4663-a8c0-67cd09b1f30c/aihw-aus-222.pdf.aspx?inline=true (accessed 15 January 2019).
The Royal Australian College of General Practitioners. General Practice: Health of the Nation 2018 [online] 2018 https://www.racgp.org.au/download/Documents/Publications/Health-of-the-Nation-2018-Report.pdf (accessed 19 March 2019).
The Pharmacy Guild of Australia. Vital facts on community pharmacy [online] 2018 https://www.guild.org.au/__data/assets/pdf_file/0024/67056/Guild_FactSheet_August2018.pdf (accessed 18 January 2019).
Caughey G. Multiple Chronic Health Conditions in Older People: Implications for Health Policy Planning, Practitioners and Patients [online] 2013 https://www.unisa.edu.au/Global/Health/Sansom/Documents/QUMPRC/Multiple-Chronic-Health-Conditions.pdf (accessed 20 October 2018).
Howarth HPG et al. Report of Health Promotion and Screening Activities by Community Pharmacists [online] 2005 http://6cpa.com.au/wp-content/uploads/Community-Pharmacy-Research-Support-Centre-final-report-health-promotion-and-screening-activities-by-community-pharmacists-.pdf (accessed 28 July 2019).
Millonig MK. White paper on expanding the role of the community pharmacist in managing depression [online] 2008 https://www.aphafoundation.org/.../WhitePaper-PharmacistRoleManagingDepression (accessed 24 August 2018).
Pharmaceutical Society of Australia. Mental Health Care Project A framework for pharmacists as partners in mental health care. [online] 2013 https://my.psa.org.au/s/article/Mental-Health-Care-Framework (accessed 1 July 2019).
Finley PR et al. Evaluating the impact of pharmacists in mental health: a systematic review. Pharmacotherapy 2003; 23: 1634-1644.
Royal Pharmaceutical Society England. Utilising pharmacists to improve the care for people with mental health problems [online] 2018 https://www.rpharms.com/Portals/0/RPS%20document%20library/Open%20access/Policy/RPS%20England%20mental%20health%20policy%202018.pdf (accessed 1 July 2019).
Hanson A et al. McCarthy's Introduction to Health Care Delivery: A Primer for Pharmacists [Book]. Massachusetts: Jones and Bartlett Learning, 2016: Available from: https://books.google.com.au/books?id=faKzDAAAQBAJ&pg=PA293#v=onepage&q&f=false.
Wright D et al. Diabetes screening through community pharmacies in England: a cost-effectiveness study. Pharmacy 2019; 7: 1-12.
Simpson SH et al. Economic impact of community pharmacist intervention in cholesterol risk management: An evaluation of the study of cardiovascular risk intervention by pharmacists. Pharmacotherapy 2001; 21: 627-635.
Perraudin C et al. Cost-effectiveness of a community pharmacist-led sleep Apnea screening program - a Markov model. PLoS One 2013; 8: e63894.
Liberati A et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700.
Higgins JPT, Deeks JJ. Chapter 7 Selecting studies and collecting data. In: Higgins JPT, Deeks JJ, eds. Cochrane Handbook for Systematic Reviews of Interventions. Chichester (UK): John Wiley & Sons, 2008: 151-183.
Higgins JPT, Altman DG. Chapter 8 Assessing risk of bias in included studies. In: Higgins JPT, Altman DG, eds. Cochrane Handbook for Systematic Reviews of Interventions. Chichester (UK): John Wiley & Sons, 2008: 187-235.
Hare SK, Kraenow K. Depression screenings: developing a model for use in a community pharmacy. J Am Pharm Assoc 2008; 48: 46-51.
Knight DE et al. Pharmacist screening for depression among patients with diabetes in an urban primary care setting. J Am Pharm Assoc 2008; 48: 518-521.
Knox ED et al. Depression screening in a university campus pharmacy: a pilot project. J Am Pharm Assoc 2006; 46: 502-506.
Rosser S et al. Development, implementation, and evaluation of a pharmacist-conducted screening program for depression. J Am Pharm Assoc 2013; 53: 22-29.
Wilson C, Twigg G. Pharmacist-led depression screening and intervention in an underserved, rural, and multi-ethnic diabetic population. J Am Pharm Assoc 2018; 58: 205-209.
Ragland D et al. Depression and diabetes: Establishing the pharmacist's role in detecting comorbidity in pregnant women. J Am Pharm Assoc 2010; 50: 195-199.
Levkoff S. Depression Screening Model for Community Pharmacy Promoting Positive Aging [online] 2006 https://communitypharmacyfoundation.org/resources/grant_docs/CPFGrantDoc_44325.pdf (accessed 1 June 2017).
Ballou JM et al. Conducting depression screenings in a community pharmacy: A pilot comparison of methods. J Am College Clin Pharm 2019; 2: 366-372.
Ito T et al. Usefulness of pharmacist-assisted screening and psychiatric referral program for outpatients with cancer undergoing chemotherapy. Psycho-Oncology 2011; 20: 647-654.
O'Reilly CL et al. A feasibility study of community pharmacists performing depression screening services. Res Soc Admin Pharm 2014; 11: 364-381.
McAlpine DD, Wilson AR. Screening for depression in primary care: What do we still need to know? Depression Anxiety 2004; 19: 137-145.
Akobeng AK. Understanding diagnostic tests 1: Sensitivity, specificity and predictive values. Acta Paediatrica, Int J Paediatr 2007; 96: 338-341.
Meader N et al. Case identification of depression in patients with chronic physical health problems: A diagnostic accuracy meta-analysis of 113 studies. Br J Gen Pract 2011; 61(593): e808-e820.
Williams JW Jr et al. Identifying depression in primary care: A literature synthesis of case-finding instruments. Gen Hospital Psychiat 2002; 24: 225-237.
Mitchell AJ, Coyne JC. Do ultra-short screening instruments accurately detect depression in primary care? A pooled analysis and meta- analysis of 22 studies. Br J Gen Pract 2007; 57(535): 144-151.
Akena D et al. Comparing the accuracy of brief versus long depression screening instruments which have been validated in low and middle income countries: A systematic review. BMC Psychiatry 2012; 12: 187.
El-Den S et al. The psychometric properties of depression screening tools in primary healthcare settings: A systematic review. J Affective Disorders 2018; 225: 503-522.
Roberts AS et al. Implementing cognitive services in community pharmacy: a review of models and frameworks for change. Int J Pharm Pract 2006; 14: 105-113.
Peterson G et al. Documenting clinical interventions in community pharmacy: PROMISe III [online] 2010 http://6cpa.com.au/wp-content/uploads/Documenting-Clinical-Interventions-in-Community-Pharmacy-PROMISe-II-Full-Final-Report-Full-Final-Report.pdf (accessed 21 September 2019).
Roberts AS et al. Understanding practice change in community pharmacy: A qualitative study in Australia. Res Soc Admin Pharm 2005; 1: 546-564.
Pignone MP et al. Screening for depression in adults: A summary of the evidence for the U.S. Preventive Services Task Force. Annals Internal Med 2002; 136: 765-776.
Hickie IB et al. Screening for depression in general practice and related medical settings. Med J Australia 2002; 177(7 SUPPL.): S111-S116.
Williams J, Nieuwsma J. Screening for depression in adults [online] 2019 https://www.uptodate.com/contents/screening-for-depression-in-adults/print (accessed 17 February 2020).
Bhattacharjee S et al. Depression screening patterns, predictors, and trends among adults without a depression diagnosis in ambulatory settings in the United States. Psychiat Services 2018; 69: 1098-1100.
Mitchell AJ et al. Case finding and screening clinical utility of the Patient Health Questionnaire (PHQ-9 and PHQ-2) for depression in primary care: a diagnostic meta-analysis of 40 studies. BJPsych Open 2016; 2: 127-138.
Australian Government. Pharmacy Trial Program [online] 2018 https://www1.health.gov.au/internet/main/publishing.nsf/Content/C517F95B09753DAFCA257F6000829193/$File/principles-pharmacy-trial-programme.pdf (accessed 16 August).
Van Bergen JEAM et al. Effectiveness and cost-effectiveness of a pharmacy-based screening programme for Chlamydia trachomatis in a high-risk health centre population in Amsterdam using mailed home-collected urine samples. Int J STD AIDS 2004; 15: 797-802.
Gordois A et al. Cost-effectiveness analysis of a pharmacy asthma care program in Australia. Disease Manage Health Outcomes 2007; 15: 387-396.
Brown RL et al. A team approach to systematic behavioral screening and intervention. Am J Managed Care 2014; 20: e113-e221.
Kearns B et al. The cost-effectiveness of changes to the care pathway used to identify depression and provide treatment amongst people with diabetes in England: a model-based economic evaluation. BMC Health Services Res 2017; 17: 1-10.
International Pharmaceutical Federation (FIP). Focus on Mental Health: The Contribution of the pharmacist. [online] 2015 https://www.fip.org/files/Focus_on_mental_health_-final.pdf (accessed 21 October 2019).
Pharmaceutical Society of Australia. Pharmacists in 2023: For patients, for our profession, for Australia’s health system [online] 2019 https://www.psa.org.au/wp-content/uploads/2019/02/Pharmacists-In-2023-digital.pdf (accessed 15 November 2019).